Nine pharma trends for 2020

Sarah Rickwood looks back at how pharma changed over the last decade and what this might mean for the industry in 2020.

The 4 biggest pharma market access stories of 2019

What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive into the pharmaphorum archives to find out.

Nine for 2019: how did we do on our predictions, and what do...

Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead.

US eyes faster launch for biosimilars in North American trad...

Celltrion gears up for subcutaneous infliximab launch in Eur...

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a p

FDA approves latest Humira near-copy, as dozens of biosimila...

The FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of these cheaper near-copies teed up to compete when the originator’s p